Lipocine doses first patient in BLOOM Phase 3 trial of oral brexanolone for postpartum depression
Lipocine announced first-patient dosing in its 120-participant Phase 3 BLOOM study of LPCN 1154, with topline results expected in the second half of 2027.
The week's only item for Lipocine is the start of dosing in its Phase 3 postpartum depression study.
- LPCN 1154, an investigational oral formulation of brexanolone, began dosing in the Phase 3 "BLOOM" trial for postpartum depression. Lipocine Inc. announced that the first participant has been dosed in BLOOM, the Company's Phase 3 study evaluating LPCN 1154 (oral brexanolone) for postpartum depression (PPD).1 The study is expected to enroll approximately 120 participants with PPD and will evaluate the same 48-hour dosing regimen and primary efficacy endpoint as the prior Phase 3 trial, change from baseline in the 17-item Hamilton Depression Rating Scale (HAM-D17) total score at 60 hours after dosing initiation.1 Topline results from the BLOOM study are expected in 2H 2027.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.